Main Article Content
Abstract
A stability-indicating reversed-phase HPLC (RP-HPLC) method was developed and validated for the simultaneous quantification of palbociclib and diclofenac, with application to forced degradation and degradation-kinetic evaluation. Separation was achieved on a C18 column (250 × 4.6 mm, 5 µm) using acetonitrile–0.02 M potassium dihydrogen phosphate buffer (55:45, v/v; pH 3.2 ± 0.1) at 1.0 mL/min with UV detection at 265 nm and a 20 µL injection volume. Diclofenac and palbociclib were eluted at 3.42 and 6.80 min, respectively, with a resolution of 4.3. The method was linear over 2–40 µg/mL (palbociclib) and 1–20 µg/mL (diclofenac) with r² = 0.9999 for both analytes. Mean recoveries ranged from 99.10–100.12% (palbociclib) and 99.38–100.50% (diclofenac), and intra-/inter-day precision was within %RSD 0.45–0.71. LOD/LOQ values were 0.4/1.2 µg/mL for palbociclib and 0.2/0.7 µg/mL for diclofenac. Forced degradation under acidic, alkaline, oxidative, neutral hydrolysis, thermal, and photolytic conditions produced 2.5–22.0% degradation with mass balance of 99.3–100.0%, confirming specificity. Kinetic assessment indicated that ln(% remaining) versus time gave the best fit, consistent with first-order degradation under the selected stress conditions. Overall, the method is suitable for routine assay, stability testing, and kinetic profiling of palbociclib–diclofenac systems.
Keywords
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.